These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 34608130)

  • 1. Combination therapy for HCC: from CRISPR screening to the design of clinical therapies.
    Wang Y; Kui L; Wang G
    Signal Transduct Target Ther; 2021 Oct; 6(1):359. PubMed ID: 34608130
    [No Abstract]   [Full Text] [Related]  

  • 2. Description of CRISPR/Cas9 development and its prospect in hepatocellular carcinoma treatment.
    Wu X; Ma W; Mei C; Chen X; Yao Y; Liu Y; Qin X; Yuan Y
    J Exp Clin Cancer Res; 2020 Jun; 39(1):97. PubMed ID: 32487115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced Nanotheranostics of CRISPR/Cas for Viral Hepatitis and Hepatocellular Carcinoma.
    Kong H; Ju E; Yi K; Xu W; Lao YH; Cheng D; Zhang Q; Tao Y; Li M; Ding J
    Adv Sci (Weinh); 2021 Dec; 8(24):e2102051. PubMed ID: 34665528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meeting Report: German Genetics Society-Genome Editing with CRISPR.
    Maier LK; Marchfelder A; Randau L
    Bioessays; 2020 Feb; 42(2):e1900223. PubMed ID: 31853989
    [No Abstract]   [Full Text] [Related]  

  • 5. Cas9 immunity creates challenges for CRISPR gene editing therapies.
    Crudele JM; Chamberlain JS
    Nat Commun; 2018 Aug; 9(1):3497. PubMed ID: 30158648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Biology and Application Areas of CRISPR Technologies.
    Adli M
    J Mol Biol; 2019 Jan; 431(1):1-2. PubMed ID: 30447221
    [No Abstract]   [Full Text] [Related]  

  • 7. Cancer Gene Discovery in Hepatocellular Carcinoma: The CRISPR/CAS9 Accelerator.
    Nault JC
    Gastroenterology; 2017 Apr; 152(5):941-943. PubMed ID: 28259794
    [No Abstract]   [Full Text] [Related]  

  • 8. Development and application of CRISPR/Cas9 technologies in genomic editing.
    Zhang C; Quan R; Wang J
    Hum Mol Genet; 2018 Aug; 27(R2):R79-R88. PubMed ID: 29659822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR/Cas9 Engineering of Adult Mouse Liver Demonstrates That the Dnajb1-Prkaca Gene Fusion Is Sufficient to Induce Tumors Resembling Fibrolamellar Hepatocellular Carcinoma.
    Engelholm LH; Riaz A; Serra D; Dagnæs-Hansen F; Johansen JV; Santoni-Rugiu E; Hansen SH; Niola F; Frödin M
    Gastroenterology; 2017 Dec; 153(6):1662-1673.e10. PubMed ID: 28923495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Charge-reversal nanocomolexes-based CRISPR/Cas9 delivery system for loss-of-function oncogene editing in hepatocellular carcinoma.
    Nie JJ; Liu Y; Qi Y; Zhang N; Yu B; Chen DF; Yang M; Xu FJ
    J Control Release; 2021 May; 333():362-373. PubMed ID: 33785418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR-Cas9 System: Opportunities and Concerns.
    Vasiliou SK; Diamandis EP; Church GM; Greely HT; Baylis F; Thompson C; Schmitt-Ulms G
    Clin Chem; 2016 Oct; 62(10):1304-11. PubMed ID: 27551006
    [No Abstract]   [Full Text] [Related]  

  • 12. CRISPR-Cas9: A revolution in genome editing in rheumatic diseases.
    Duroux-Richard I; Giovannangeli C; Apparailly F
    Joint Bone Spine; 2017 Jan; 84(1):1-4. PubMed ID: 27825565
    [No Abstract]   [Full Text] [Related]  

  • 13. Twelve genes at one blow: multiplex genome editing with CRISPR/Cas.
    Verhage L
    Plant J; 2021 Apr; 106(1):6-7. PubMed ID: 33861513
    [No Abstract]   [Full Text] [Related]  

  • 14. CRISPR-Cas9 for cancer therapy: Opportunities and challenges.
    Chen M; Mao A; Xu M; Weng Q; Mao J; Ji J
    Cancer Lett; 2019 Apr; 447():48-55. PubMed ID: 30684591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Refining CRISPR-based genome and epigenome editing off-targets.
    Luo Y
    Cell Biol Toxicol; 2019 Aug; 35(4):281-283. PubMed ID: 31227932
    [No Abstract]   [Full Text] [Related]  

  • 16. Foresight is 2020: Ten Bold Predictions for the New CRISPR Year.
    Barrangou R
    CRISPR J; 2019 Dec; 2(6):341-342. PubMed ID: 31860348
    [No Abstract]   [Full Text] [Related]  

  • 17. [CRISPR-Cas system as molecular scissors for gene therapy].
    Heinz GA; Mashreghi MF
    Z Rheumatol; 2017 Feb; 76(1):46-49. PubMed ID: 28124743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of CRISPR/Cas Genome Editing Technology for Targeted Mutagenesis in Rice.
    Xu R; Wei P; Yang J
    Methods Mol Biol; 2017; 1498():33-40. PubMed ID: 27709567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whole-body CRISPR editing.
    Perdigoto CN
    Nat Struct Mol Biol; 2022 Aug; 29(8):729. PubMed ID: 35948771
    [No Abstract]   [Full Text] [Related]  

  • 20. Assessing Off-Target Editing of CRISPR-Cas9 Systems.
    Pruett-Miller SM
    CRISPR J; 2020 Dec; 3(6):430-432. PubMed ID: 33346715
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.